Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Publication year range
1.
Circ J ; 86(2): 256-265, 2022 01 25.
Article in English | MEDLINE | ID: mdl-34334554

ABSTRACT

BACKGROUND: The use of iodine contrast agents is one possible limitation in cryoballoon ablation (CBA) for atrial fibrillation (AF). This study investigated intracardiac echography (ICE)-guided contrast-free CBA.Methods and Results:The study was divided into 2 phases. First, 25 paroxysmal AF patients (Group 1) underwent CBA, and peri-balloon leak flow velocity (PLFV) was assessed using ICE and electrical pulmonary vein (PV) lesion gaps were assessed by high-density electroanatomical mapping. Then, 24 patients (Group 2) underwent ICE-guided CBA and were compared with 25 patients who underwent conventional CBA (historical controls). In Group 1, there was a significant correlation between PLFV and electrical PV gap diameter (r=-0.715, P<0.001). PLFV was higher without than with an electrical gap (mean [±SD] 127.0±28.6 vs. 66.6±21.0 cm/s; P<0.001) and the cut-off value of PLFV to predict electrical isolation was 105.7 cm/s (sensitivity 0.700, specificity 0.929). In Group 2, ICE-guided CBA was successfully performed with acute electrical isolation of all PVs and without the need for "rescue" contrast injection. Atrial tachyarrhythmia recurrence at 6 months did not differ between ICE-guided and conventional CBA (3/24 [12.5%] vs. 5/25 [20.0%], respectively; P=0.973, log-rank test). CONCLUSIONS: PLFV predicted the presence of an electrical PV gap after CBA. ICE-guided CBA was feasible and safe, and could potentially be performed completely contrast-free without a decrease in ablation efficacy.


Subject(s)
Atrial Fibrillation , Catheter Ablation , Cryosurgery , Pulmonary Veins , Atrial Fibrillation/diagnostic imaging , Atrial Fibrillation/surgery , Catheter Ablation/methods , Cryosurgery/adverse effects , Cryosurgery/methods , Echocardiography/methods , Humans , Pulmonary Veins/diagnostic imaging , Pulmonary Veins/surgery , Recurrence , Treatment Outcome
2.
J Atheroscler Thromb ; 28(9): 954-962, 2021 Sep 01.
Article in English | MEDLINE | ID: mdl-33100279

ABSTRACT

AIM: The predictors of restenosis after endovascular therapy (EVT) with paclitaxel drug-coated balloons (DCBs) have not been clearly established. The present study aimed to investigate the association of post-procedural dissection, as evaluated using intravascular ultrasound (IVUS), with the risk of restenosis following femoropopliteal EVT with paclitaxel DCBs. METHODS: In the present single-center retrospective study, 60 de novo femoropopliteal lesions (44 patients) that underwent EVT with DCBs, without bail-out stenting, were enrolled. The primary outcome was 1-year primary patency. Risk factors for restenosis were evaluated using a Cox proportional hazards regression model and random survival forest analysis. RESULTS: The 1-year primary patency rate was 57.2% [95% confidence interval, 45%-72%]. IVUS-evaluated post-procedural dissection was significantly associated with the risk of restenosis (P=0.002), with the best cutoff point of 64º [range, 39º-83º]. The random survival forest analysis showed that the variable importance measure of IVUS-evaluated dissection was significantly lower than that of the reference vessel diameter (P<0.001), not different from that of the lesion length (P=0.41), and significantly higher than that of any other clinical feature (all P<0.05). CONCLUSION: IVUS-evaluated post-procedural dissection was associated with 1-year restenosis following femoropopliteal EVT with DCB.


Subject(s)
Endovascular Procedures , Paclitaxel/therapeutic use , Peripheral Arterial Disease/therapy , Tubulin Modulators/therapeutic use , Vascular Access Devices , Aged , Aged, 80 and over , Constriction, Pathologic/diagnosis , Constriction, Pathologic/etiology , Endovascular Procedures/adverse effects , Female , Humans , Male , Paclitaxel/administration & dosage , Peripheral Arterial Disease/diagnosis , Prognosis , Retrospective Studies , Treatment Outcome , Tubulin Modulators/administration & dosage , Vascular Access Devices/adverse effects
3.
Rinsho Ketsueki ; 59(5): 492-494, 2018.
Article in Japanese | MEDLINE | ID: mdl-29877236

ABSTRACT

Here, we report a case of a 67-year-old man who had septic shock due to Citrobacter braakii infection during the course of chemotherapy with high-dose cytosine arabinoside for acute myeloid leukemia. Treatment with cefepime rapidly improved his condition. The number of reported cases of sepsis due to Citrobacter braakii is limited. Further accumulation of cases is necessary to obtain accurate data such as the risk factors for Citrobacter braakii infections.


Subject(s)
Enterobacteriaceae Infections/complications , Leukemia, Myeloid, Acute , Shock, Septic , Aged , Citrobacter , Cytarabine , Humans , Leukemia, Myeloid, Acute/complications , Male , Shock, Septic/etiology
SELECTION OF CITATIONS
SEARCH DETAIL